NorthWest Biotherapeutics Inc (NWBO)

[ou71764]

The patient's dendritic cells are losing ground to the cancer at the time of the surgery and preparation of the vaccine. That's the prima facie case for saying that a dendritic vaccine is too weak to defeat cancer - the immune system is already failing.

Why the immune system starts to fail may be critical. If it's a case that the cancer has mutated and tricked the dendritic cells, then IMO (as a layman, I'm not a scientist) the vaccine should work.

I believe the vaccine is created outside the patient with newly formed dendritic cells. Those cells are allowed to mix with the tumor and identify the cancer as the enemy with 100% accuracy.
It's those newly formed dendritic cells that are going to be injected into the patient to activate the immune system to fight the cancer.

There is no sure thing in the biotech world. It's why they do the trials. But given the skepticism over the odds of success, you can be sure that if the vaccine is successful, the stock price will be many times the current price.